Compare APAM & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APAM | VERA |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | 2011 | 2021 |
| Metric | APAM | VERA |
|---|---|---|
| Price | N/A | $42.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | | 10 |
| Target Price | N/A | $81.30 |
| AVG Volume (30 Days) | N/A | 1.4M |
| Earning Date | 06-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $472.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $19.07 |
| 52 Week High | N/A | $56.05 |
| Indicator | APAM | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 41.35 | 71.97 |
| Support Level | N/A | $40.87 |
| Resistance Level | $38.07 | $42.77 |
| Average True Range (ATR) | 1.03 | 1.94 |
| MACD | -0.08 | 1.09 |
| Stochastic Oscillator | 25.25 | 89.55 |
Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. The company operates as one segment in the investment management business. The company generates maximum portion of its revenues from clients domiciled in countries outside the United States.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.